Elisabeth Arndal

Medicine & Life Sciences

1. SARS Virus 100%
2. Smell 64%
3. Pulmonary Diffusing Capacity 58%
4. Taste Disorders 56%
5. Quality of Life 51%
6. Prospective Studies 48%
7. Cohort Studies 48%
8. Nose 47%
9. Nasal Polyps 45%
10. Fibrin Tissue Adhesive 44%
11. Dysgeusia 43%
12. Single-Photon Emission-Computed Tomography 35%
13. Comorbidity 32%
14. Lung Diseases 31%
15. Chronic Obstructive Pulmonary Disease 31%
16. Sino-Nasal Outcome Test 30%
17. Pulmonary Fibrosis 27%
18. Anti-Bacterial Agents 27%
19. Outpatients 26%
20. Thorax 26%
21. Vascular Diseases 22%
22. Intensive Care Units 19%
23. Ventilation-Perfusion Scan 17%
24. Total Lung Capacity 15%
25. Lung Volume Measurements 15%
26. Platelet-Rich Fibrin 15%
27. Therapeutics 13%
28. Colistin 12%
29. Cystic Fibrosis 12%
30. Inflammation 12%
31. Carbon Monoxide 12%
32. Sinusitis 11%
33. Glass 11%
34. Steroids 10%
35. Olfaction Disorders 10%
36. Hemoglobins 9%
37. Pseudomonas aeruginosa 9%
38. Lung 9%
39. Polyps 9%
40. Perfusion 8%
41. Nasal Lavage 8%
42. Pharynx 7%
43. Infections 7%
44. Monoclonal Antibodies 6%
45. Tobramycin 6%
46. Ear 6%
47. Immunoglobulin E 5%
48. Visual Analog Scale 5%
49. Mucus 5%
50. Ciprofloxacin 5%